Skip to content

Study on the characterization of RAS-associated systemic lupus erythematosus (SLE)

Study on the characterization of RAS-associated systemic lupus erythematosus (SLE)

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
DRKS
Registry ID
DRKS00037195
Enrollment
15
Registered
2025-07-09
Start date
2025-08-15
Completion date
Unknown
Last updated
2026-03-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Systemic Lupus Erythematosus (SLE) M32, Monogenic RASopathies, SHOC2 gain-of-function

Interventions

Group 1: For study participants, peripheral blood will primarily be collected for phenotypic and functional assessment of leukocytes whenever possible during medically necessary blood draws. In some c

Sponsors

Haunersche Kinderpoliklinik
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Patients with a diagnosed genetic disease are eligible for recruitment

Exclusion criteria

Exclusion criteria: Lack of informed consent from the probands or their parents in the case of underaged-probands Reaching of adulthood and lack of informed consent at this stage

Design outcomes

Primary

MeasureTime frame
The aim of the study is to systematically characterize the immunological, clinical, and age-dependent features of a rare, severe monogenic disease across the lifespan in order to better understand its pathophysiology and identify potential targets for future therapies.

Secondary

MeasureTime frame
Discovery of molecular causes of defective immune tolerance

Countries

Germany

Contacts

Public ContactJonathan Bohlen

Genzentrum der LMU

bohlen@genzentrum.lmu.de+49 89-2180-71055

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Apr 4, 2026